PT1086082E - Aminas olefinicas substituidas com arilo e seu uso como agonistas de receptores colinergicos - Google Patents
Aminas olefinicas substituidas com arilo e seu uso como agonistas de receptores colinergicosInfo
- Publication number
- PT1086082E PT1086082E PT99926152T PT99926152T PT1086082E PT 1086082 E PT1086082 E PT 1086082E PT 99926152 T PT99926152 T PT 99926152T PT 99926152 T PT99926152 T PT 99926152T PT 1086082 E PT1086082 E PT 1086082E
- Authority
- PT
- Portugal
- Prior art keywords
- methyl
- amine
- penten
- pyridyl
- arylium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9828598A | 1998-06-16 | 1998-06-16 | |
US09/098,133 US6232316B1 (en) | 1998-06-16 | 1998-06-16 | Methods for treatment of CNS disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1086082E true PT1086082E (pt) | 2005-01-31 |
Family
ID=26794206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99926152T PT1086082E (pt) | 1998-06-16 | 1999-06-03 | Aminas olefinicas substituidas com arilo e seu uso como agonistas de receptores colinergicos |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1086082B9 (es) |
JP (4) | JP4240815B2 (es) |
KR (1) | KR100593433B1 (es) |
AT (1) | ATE273956T1 (es) |
AU (1) | AU4230799A (es) |
BR (1) | BR9911325A (es) |
CA (3) | CA2677519A1 (es) |
DE (1) | DE69919537T2 (es) |
DK (1) | DK1086082T3 (es) |
ES (1) | ES2228054T3 (es) |
PT (1) | PT1086082E (es) |
WO (1) | WO1999065876A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979695B2 (en) * | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
JP4240815B2 (ja) * | 1998-06-16 | 2009-03-18 | ターガセプト,インコーポレイテッド | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
JP2003501416A (ja) * | 1999-06-07 | 2003-01-14 | ターガセプト,インコーポレイテッド | 医薬組成物およびその使用法 |
CA2383307A1 (en) * | 1999-08-31 | 2001-03-08 | Jared Miller Wagner | Arylalkyloxyalkylamines and arylalkylthioalkylamines, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
AU2001257449A1 (en) * | 2000-05-01 | 2001-11-12 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
US6432954B1 (en) * | 2000-07-14 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
NZ554913A (en) | 2001-12-14 | 2009-01-31 | Targacept Inc | Methods and compositions for the treatment of central nervous system disorders |
US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
DK1678172T3 (da) | 2003-10-15 | 2010-04-06 | Targacept Inc | Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet |
UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
EP2357174A1 (en) | 2006-05-09 | 2011-08-17 | AstraZeneca AB | Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine |
TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
EP2083921A2 (en) | 2006-09-04 | 2009-08-05 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
US20100247617A1 (en) * | 2007-07-31 | 2010-09-30 | Targacept, Inc. | Transdermal Administration Of (2S)-(4E)-N-Methyl-5-(3-(5-Isopropoxypyridin)yl)-4-Penten-2-Amine |
WO2010009775A1 (de) | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
US8703775B2 (en) | 2007-12-07 | 2014-04-22 | AbbVie Deutschland GmbH & Co. KG | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
CN102026995B (zh) | 2007-12-07 | 2014-10-29 | Abbvie德国有限责任两合公司 | 5,6-二取代的羟吲哚衍生物和其用途 |
BRPI0820668A2 (pt) | 2007-12-07 | 2017-08-22 | Abbott Gmbh & Co Kg | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina |
US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
JP2011516489A (ja) | 2008-03-31 | 2011-05-26 | ユニバーシティ・オブ・サウス・フロリダ | 疾患誘発性運動失調症および非運動失調性平衡異常の治療法 |
US9040568B2 (en) | 2009-05-29 | 2015-05-26 | Abbvie Inc. | Pharmaceutical compositions for the treatment of pain |
SG185497A1 (en) * | 2010-05-20 | 2012-12-28 | Astrazeneca Ab | New process for the preparation of aryl substituted olefinic amines |
WO2013184732A1 (en) * | 2012-06-06 | 2013-12-12 | Targacept, Inc. | Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242935A (en) * | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5597716A (en) * | 1993-11-18 | 1997-01-28 | Mitsubishi Rayon Co., Ltd. | Process for producing D-lactic acid and L-lactamide |
US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
JP3899126B2 (ja) * | 1995-01-06 | 2007-03-28 | ターガセプト,インコーポレイテッド | 中枢神経系疾患の予防及び治療のための医薬組成物 |
US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
AU5383196A (en) * | 1995-05-17 | 1996-11-29 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
EP0900200B9 (en) * | 1996-04-23 | 2009-10-21 | Targacept, Inc. | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5629325A (en) * | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
AU749151B2 (en) * | 1997-02-21 | 2002-06-20 | Targacept, Inc. | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
JP4240815B2 (ja) * | 1998-06-16 | 2009-03-18 | ターガセプト,インコーポレイテッド | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
-
1999
- 1999-06-03 JP JP2000554703A patent/JP4240815B2/ja not_active Expired - Fee Related
- 1999-06-03 KR KR1020007014279A patent/KR100593433B1/ko not_active IP Right Cessation
- 1999-06-03 ES ES99926152T patent/ES2228054T3/es not_active Expired - Lifetime
- 1999-06-03 CA CA002677519A patent/CA2677519A1/en not_active Abandoned
- 1999-06-03 AU AU42307/99A patent/AU4230799A/en not_active Abandoned
- 1999-06-03 DK DK99926152T patent/DK1086082T3/da active
- 1999-06-03 BR BR9911325-2A patent/BR9911325A/pt not_active Application Discontinuation
- 1999-06-03 WO PCT/US1999/012340 patent/WO1999065876A1/en active IP Right Grant
- 1999-06-03 DE DE69919537T patent/DE69919537T2/de not_active Expired - Lifetime
- 1999-06-03 PT PT99926152T patent/PT1086082E/pt unknown
- 1999-06-03 CA CA002334923A patent/CA2334923C/en not_active Expired - Fee Related
- 1999-06-03 CA CA2709735A patent/CA2709735A1/en not_active Abandoned
- 1999-06-03 EP EP99926152A patent/EP1086082B9/en not_active Expired - Lifetime
- 1999-06-03 AT AT99926152T patent/ATE273956T1/de active
-
2008
- 2008-05-19 JP JP2008130502A patent/JP4972608B2/ja not_active Expired - Fee Related
- 2008-05-19 JP JP2008130504A patent/JP4896923B2/ja not_active Expired - Fee Related
-
2010
- 2010-06-15 JP JP2010135746A patent/JP2010229149A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU4230799A (en) | 2000-01-05 |
DK1086082T3 (da) | 2004-11-22 |
DE69919537T2 (de) | 2005-09-08 |
JP2008260774A (ja) | 2008-10-30 |
JP2010229149A (ja) | 2010-10-14 |
CA2677519A1 (en) | 1999-12-23 |
DE69919537D1 (de) | 2004-09-23 |
EP1086082B1 (en) | 2004-08-18 |
JP2008255122A (ja) | 2008-10-23 |
ATE273956T1 (de) | 2004-09-15 |
JP4896923B2 (ja) | 2012-03-14 |
EP1086082A1 (en) | 2001-03-28 |
CA2334923A1 (en) | 1999-12-23 |
CA2709735A1 (en) | 1999-12-23 |
WO1999065876A1 (en) | 1999-12-23 |
ES2228054T3 (es) | 2005-04-01 |
JP4972608B2 (ja) | 2012-07-11 |
KR100593433B1 (ko) | 2006-06-28 |
KR20010083052A (ko) | 2001-08-31 |
CA2334923C (en) | 2009-09-29 |
JP4240815B2 (ja) | 2009-03-18 |
BR9911325A (pt) | 2001-04-03 |
JP2002518373A (ja) | 2002-06-25 |
EP1086082B9 (en) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1086082E (pt) | Aminas olefinicas substituidas com arilo e seu uso como agonistas de receptores colinergicos | |
BR9810342A (pt) | Novos compostos imidazola substituìdos | |
DE60008133D1 (de) | Farbstoff-markierte imidazochinolinverbindungen | |
PA8637601A1 (es) | Compuestos moduladores de la actividad de c-kit y usos de los mismos | |
TR200000782T2 (tr) | Resorsinol türevleri. | |
TR200300322T2 (tr) | Kemokin alıcısını bağlayan heterosiklik bileşikler | |
TR200100922T2 (tr) | Aktif maddelerin akciğerler yolu ile tatbik edilmesi. | |
BR0115400A (pt) | Compostos de piperazinilpirazina atuando como agonistas ou antagonistas do receptor 5ht-2 de serotonina | |
TR200102029T2 (tr) | 1-Heterosiklil ikameli diarilaminler. | |
PT1214936E (pt) | Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos | |
UY27098A1 (es) | Derivados de indol | |
TW200607814A (en) | Cell surface receptor isoforms and methods of identifying and using the same | |
PT1093819E (pt) | Compostos e composicoes para fornecimento de agentes activos | |
ES2187200T3 (es) | Proteina hibrida para inhibir la desgranulacion de mastocitos y su uso. | |
ID26328A (id) | Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril | |
PT935465E (pt) | Compostos novos de imidazole substituido | |
PT1117659E (pt) | Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas | |
ATE296348T1 (de) | Cytokin lerk-7 | |
PT888384E (pt) | Polipeptido de fusao para influenciar as interaccoes entre proteinas | |
ATE243993T1 (de) | Verwendung von 5ht3 antagonisten zum fördern der darmspülung | |
EA200300593A1 (ru) | Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора | |
BR9909486A (pt) | Compostos calcilìticos | |
BR0107770A (pt) | Derivados de 3-fenóxi-1-fenil acetileno e seu uso como herbicidas | |
BR0007864A (pt) | Composto, e, uso de um composto | |
ATE267596T1 (de) | Cyanidinzusammensetzungen und deren therapeutische und diagnostische verwendungen |